{
  "docId": "019de073-42e0-708e-bbdb-4616fa343de3",
  "docSlug": "252a92bcbab8bda657ee7494bf765251",
  "documentTitle": "BioAtla | Investor Presentation Deck | 37 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 37,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a comparative visual framework to contrast healthy cells (no binding) with cancer cells (CAB binding).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-42e0-708e-bbdb-4616fa343de3/5",
  "deckHref": "/decks/019de073-42e0-708e-bbdb-4616fa343de3",
  "deckJsonHref": "/decks/019de073-42e0-708e-bbdb-4616fa343de3.json",
  "deckAnchorHref": "/decks/019de073-42e0-708e-bbdb-4616fa343de3#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.38,
        "x": 0.58,
        "y": 0.25
      },
      "kind": "image",
      "text": "Comparative diagram showing healthy cell membrane (alkaline) vs cancer cell membrane (acidic) and the resulting CAB binding behavior.",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63f06ac5-eae2-4475-b369-10ce84aa72cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.11,
        "y": 0.28
      },
      "kind": "list",
      "text": "BioAtla discovered that acidic pH at the cancer cell surface unveils binding sites that are shielded at normal pH of healthy cells. BioAtla invented CAB technology, creating antibodies that bind only to these unveiled sites on cancer cells. CAB binding region is not masked or caged and thus different from prodrugs that require irreversible enzymatic cleavage to become activated. CAB antibodies have the potential for increased efficacy with improved safety relative to traditional antibodies.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2cf5930-c5be-43df-8aa9-7012c3e96d0d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.58,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Chang, H.W., Frey, G., Liu, H., Xing, C., Steinman, L., Boyle, B.J., & Short, J.M. (2021) PNAS 118(9): 1-10, Suppl. 1-19.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b722423f-08bf-48b7-8a6e-2400bba7a470",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Selective and targeted CAB technology widens therapeutic window, thus has the potential to enhance clinical outcomes in multiple tumor types",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "014b815e-aa75-417b-a7a0-8b1a7c50fb09",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "b88ac5ad-890b-44cd-bfe4-7484d888ee88",
      "evidence": "Contrasts healthy cell state (no binding) with cancer cell state (binding) to demonstrate efficacy.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 5,
      "from": 5,
      "beatId": "6330ddf1-883e-4ebe-ac08-a0e6039b0a3b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The solution section presents BioAtla's CAB technology as a potential solution to the problem.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}